Abstract
Pelvic radiation therapy with concurrent chemotherapy is the standard of care for locally advanced cervical carcinoma. While effective, this treatment approach is associated with acute hematologic toxicity. Published literature reports that pelvic bone marrow (BM) dosimetric parameters of V10>90%, V10>85%, and V20>80% are associated with higher rates of hematologic toxicity. In this study, we sought to investigate the ability of TomoTherapy based BM sparing intensity modulated radiation therapy (BMS-IMRT) in reducing dose to the pelvic BM while evaluating the dose distribution to nearby critical structures and effect on PTV coverage.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
